Louise Rodino-Klapac
2020
Compensation breakdown
| Non-Equity Incentive Plan | $229,932 |
|---|---|
| Option Awards | $5,763,506 |
| Salary | $495,590 |
| Stock Awards | $766,949 |
| Other | $13,532 |
| Total | $7,269,509 |
Rodino-Klapac received $5.8M in option awards, accounting for 79% of the total pay in 2020.
Rodino-Klapac also received $229.9K in non-equity incentive plan, $495.6K in salary, $766.9K in stock awards and $13.5K in other compensation.
Rankings
In 2020, Louise Rodino-Klapac's compensation ranked 1,326th out of 13,090 executives tracked by ExecPay. In other words, Rodino-Klapac earned more than 89.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,326 out of 13,090 | 90th |
Division Manufacturing | 479 out of 5,617 | 92nd |
Major group Chemicals And Allied Products | 169 out of 2,248 | 93rd |
Industry group Drugs | 145 out of 1,948 | 93rd |
Industry Pharmaceutical Preparations | 105 out of 1,453 | 93rd |
Pay ratio
| Louise Rodino-Klapac's Pay | $7,269,509 |
|---|---|
| Median Employee's Pay | $275,247 |
| Pay Ratio | 26to 1 |
In 2020, the annual total compensation of Louise Rodino-Klapac was $7,269,509.
The annual total compensation of the median employee at Sarepta Therapeutics was $275,247.
The ratio of Louise Rodino-Klapac's pay to the pay of median employee was therefore 26 to one.
Rodino-Klapac's colleagues
We found seven more compensation records of executives who worked with Louise Rodino-Klapac at Sarepta Therapeutics in 2020.
2020
David Howton
Sarepta Therapeutics
General Counsel
2020
Ian Estepan
Sarepta Therapeutics
Chief Financial Officer
2020
Gilmore MMSc
Sarepta Therapeutics
Chief Scientific Officer
2020
Sandesh Mahatme
Sarepta Therapeutics
Chief Financial Officer
2020
Douglas Ingram
Sarepta Therapeutics
Chief Executive Officer
2020
Joseph Bratica
Sarepta Therapeutics
Vice President, Corporate Controller
2020
William Ciambrone
Sarepta Therapeutics